rs104894064
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PM5PP5_Very_Strong
The NM_018941.4(CLN8):c.70C>G(p.Arg24Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000421 in 1,613,806 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R24H) has been classified as Likely pathogenic.
Frequency
Genomes: 𝑓 0.000086 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000038 ( 0 hom. )
Consequence
CLN8
NM_018941.4 missense
NM_018941.4 missense
Scores
5
5
4
Clinical Significance
Conservation
PhyloP100: 5.44
Genes affected
CLN8 (HGNC:2079): (CLN8 transmembrane ER and ERGIC protein) This gene encodes a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with a disorder characterized by progressive epilepsy with cognitive disabilities (EPMR), which is a subtype of neuronal ceroid lipofuscinoses (NCL). Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain. [provided by RefSeq, Jul 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM1
?
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 11 uncertain in NM_018941.4
PM2
?
Very rare variant in population databases, with high coverage;
PM5
?
Other missense variant is known to change same aminoacid residue: Variant chr8-1771125-G-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 2157339.Status of the report is criteria_provided_single_submitter, 1 stars.
PP5
?
Variant 8-1771124-C-G is Pathogenic according to our data. Variant chr8-1771124-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 2802.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-1771124-C-G is described in UniProt as null. Variant chr8-1771124-C-G is described in Lovd as [Likely_pathogenic]. Variant chr8-1771124-C-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CLN8 | NM_018941.4 | c.70C>G | p.Arg24Gly | missense_variant | 2/3 | ENST00000331222.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CLN8 | ENST00000331222.6 | c.70C>G | p.Arg24Gly | missense_variant | 2/3 | 1 | NM_018941.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000856 AC: 13AN: 151920Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
13
AN:
151920
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000103 AC: 26AN: 251484Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135914
GnomAD3 exomes
AF:
AC:
26
AN:
251484
Hom.:
AF XY:
AC XY:
14
AN XY:
135914
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000376 AC: 55AN: 1461886Hom.: 0 Cov.: 32 AF XY: 0.0000330 AC XY: 24AN XY: 727244
GnomAD4 exome
AF:
AC:
55
AN:
1461886
Hom.:
Cov.:
32
AF XY:
AC XY:
24
AN XY:
727244
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000856 AC: 13AN: 151920Hom.: 0 Cov.: 32 AF XY: 0.0000944 AC XY: 7AN XY: 74182
GnomAD4 genome
?
AF:
AC:
13
AN:
151920
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
74182
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ExAC
?
AF:
AC:
5
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neuronal ceroid lipofuscinosis 8 northern epilepsy variant Pathogenic:1Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 11, 2020 | - - |
Basal cell carcinoma, susceptibility to, 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 28, 2024 | Variant summary: PTCH2 c.70C>G (p.Gln24Glu) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4.5e-05 in 155326 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.70C>G in individuals affected with Basal Cell Carcinoma, Susceptibility To, 1 and no experimental evidence demonstrating its impact on protein function have been reported. One submitter has cited clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Neuronal ceroid lipofuscinosis 8 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Mar 08, 2016 | - - |
Neuronal ceroid lipofuscinosis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Mar 29, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change does not substantially affect CLN8 function (PMID: 10861296, 15160397). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CLN8 protein function. ClinVar contains an entry for this variant (Variation ID: 2802). This missense change has been observed in individuals with progressive epilepsy with mental retardation, also known as Northern epilepsy (PMID: 10508524, 16828266). It is commonly reported in individuals of Finnish ancestry (PMID: 10508524, 16828266). This variant is present in population databases (rs104894064, gnomAD 0.1%). This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 24 of the CLN8 protein (p.Arg24Gly). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Uncertain
Dann
Uncertain
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;.;.;.;.;T;.;T;T
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationTaster
Benign
A
PrimateAI
Uncertain
T
Sift4G
Benign
T;D;.;.;.;.;.;T;.
Polyphen
0.99
.;D;D;D;D;.;D;.;.
Vest4
0.91
MutPred
Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);Gain of relative solvent accessibility (P = 0.1259);
MVP
0.96
MPC
0.28
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at